GSK announced on January 20 that its portfolio company, Tesaro, will acquire Alteogen’s novel hyaluronidase enzyme ALT-B4 for $20 million. Alteogen developed ALT-B4 using its bespoke Hybrozyme technology, which the company notes was designed to boost the flexibility and stability of protein structures while preserving the enzyme’s original mechanism of action. […]
The post GSK’s Tesaro Acquires Alteogen’s ALT-B4 appeared first on LevinPro Healthcare M&A – The latest healthcare M&A news.
